Report on Psychedelics

In the Research Briefing:

- Flashbacks are common in psychedelic research but participants don't seem to mind

- LSD influences creativity, breaking down thought patterns and relocating them toward the new

- Psychedelics and society; thought on the past, present and future

In the Research Briefing:

- Ketamine effective in abstaining from alcohol for up to 6 months later

- Real-world data provides further evidence ketamine therapy is effective for depression

- But a large study finds ketamine not to be effective for PTSD in service members

In This Industry Briefing:

-Canada approves psychedelics for the SAP.

-Lexston's psychedelic journey.

-Nucleus, the data driven solution?

-Cannabis Vs. Psychedelics, the early days.

-Otsuka makes an investment into psychedelics.

In the Research Briefing

- Psilocybin can be administered safely for up to six people simultaneously

- An Open Science approach toward MDMA synthesis

- Nitrous Oxide could be the next antidepressant

In the Report:

-New double blind study does not find benefits of microdosing

-The negative post-acute effects of MDMA appear to be absent in the clinical setting.

In This Briefing:

The last few weeks have been a bit light on the side of psychedelic news. Whether it is because we are coming to the end of 2021 or for other reasons. Sometimes, a light week or 2 is a good thing, maybe the industry needs a bit of a news break.

In The Research Briefing:

- The methodological challenges faced in psychedelic clinical trials (and how to fix them)

- Mystical experiences in recreational use associated with improvements in wellbeing

- A novel 5-MeO-DMT formulation proves to be safe in Phase I trial

In this briefing:

A look at the psychedelics industry? How did we get to where we are? How can we get past the lull? Who should consumers trust?

But first, a few good news stories to start off, reducing the timelines of therapy, and some promising microdosing data!

In The Research Briefing:

- Those who microdose report lower levels of anxiety & depression

- Psilocybin therapy increases cognitive and neural flexibility

- And how can psilocybin help decrease craving in alcoholism

In this episode of the ROP Speakers Series, we talk to Adam Deffett, the Interim CEO for Ketamine One. We talk about all things ketamine, where the company is going, the market outlook, and some new and interesting items from the world of psychedelics.